Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms

Area of Science:

• Neurology
• Radiology
• Data Science

Background:

• Current definitions of multiple sclerosis (MS) relapses rely on clinical worsening and radiological progression, but these often show discordance.
• This discrepancy complicates accurate assessment of acute relapses in Phase 3 clinical studies, leaving the true incidence unclear.
• Existing definitions may not fully capture the pathological events occurring during an acute MS relapse.

Discussion:

• Magnetic resonance imaging (MRI) offers objective, sensitive, and standardized data for diagnosing MS relapses.
• Breach of the blood-brain barrier, visualized via MRI, is proposed as a more precise indicator of acute relapse.
• The limitations of current clinical definitions in capturing radiological progression are highlighted.

Key Insights:

• MRI data provides advantages in sensitivity, standardization, and unbiased analysis for MS relapse detection.
• A revised definition of acute MS relapse focusing on blood-brain barrier integrity via MRI is suggested.
• This shift could improve the accuracy of patient selection in clinical trials and drug development.

Outlook:

• Emerging "big data" concepts and advanced MRI techniques are transforming MS diagnosis and treatment.
• Standardized and shared MRI data can accelerate the development of more effective MS therapies and endpoints.
• Neurology is increasingly leveraging big data and advanced imaging for a comprehensive approach to MS management.